Back to top

Analyst Blog

On April 1, we have updated our research report on Covidien plc (COV - Analyst Report). We are impressed with the company’s recent fiscal 2014 first quarter results but remains concerned about stiff competition and pricing and utilization headwinds in certain end markets.

Covidien posted a 3.1% rise in first-quarter fiscal 2014 adjusted earnings per share to $1.00, which beat the Zacks Consensus Estimate by 6 cents. Despite facing headwinds from foreign exchange movements, the medical device excise tax and incremental investments in emerging markets, the company managed to deliver a positive earnings surprise in the quarter.

Revenues in the quarter grew 2.8% (up 5% in constant currency) to $2,639 million, exceeding the Zacks Consensus Estimate by 1.4%. On a geographic basis, revenues in the U.S. market increased 3.0% to $1,307 million. On the other hand, international revenues increased 2.6% to $1,332 million, driven by growth of 11.5% in emerging markets.

Covidien reiterated its outlook for fiscal 2014. Covidien expects revenues to grow 2–5% year over year at constant exchange rate for fiscal 2014. Further, the company aims to achieve a dividend payout ratio in excess of 35% over time and is targeting to attain a ratio of at least 30% within the next 12 months.

Covidien is expanding its footprint in the emerging markets, notably in Eastern Europe, Middle East and Africa, Asia and Latin America, and boosting market share in core segments through investments in sales and marketing infrastructure.

Covidien's core Medical Device business overlaps with the business of its competitors like Johnson & Johnson (JNJ - Analyst Report), Becton, Dickinson and Company (BDX - Analyst Report), and CR Bard Inc. (BCR - Analyst Report). Therefore, market share gains by these competitors remain an overhang.

Currently, Covidien retains a Zacks Rank #3 (Hold).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
PLANAR SYST… PLNR 4.44 +5.21%
BITAUTO HOL… BITA 81.71 +5.12%
CTPARTNERS… CTP 16.66 +4.26%
CHINA BIOLO… CBPO 47.91 +3.30%
MALLINCKROD… MNK 72.94 +2.85%